

Effective **May 1, 2021**, the Alberta Biosimilars Initiative will be updated with the following changes that will affect adult members on Alberta government-sponsored drug plans.

Addition of adalimumab biosimilars – all adult patients on Humira must switch by May 1, 2022

1. Update to Alberta Drug Benefit List (ADBL)

On May 1, 2021, five new adalimumab biosimilar drugs, Amgevita, Hadlima, Hulio, Hyrimoz, and Idacio were listed on the Alberta Drug Benefit List (ADBL) for the treatment of ankylosing spondylitis, hidradenitis suppurativa, Crohn's disease, plaque psoriasis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis and will be subject to the Alberta Biosimilar Initiative.

2. Special Authorization requests

Effective May 1, 2021, all Special Authorization requests for new adalimumab starts for the above indications will be assessed for coverage with a biosimilar version of adalimumab. Adult patients currently taking Humira will be required to switch to a biosimilar version by May 1, 2022 to maintain coverage for this molecule through their Alberta government-sponsored drug plan.